Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 22, Issue 1, Pages 9-34Publisher
INFORMA HEALTHCARE
DOI: 10.1517/13543784.2013.739605
Keywords
5-FU; AGS-16M18; AGS-8M4; ASP-6183; ALS-357; AMG-102; AMG-655; AMG-951; amolimogene bepiplasmid; amonafide malate; AS-1413; AZD-2461; AZD-4769; AZD-7762; AZD-8055; betulinic acid; biotope-CD; conatumumab; CVX-241; dacetuzumab; davanat-1; dulanermin; EMD-1204831; figitumumab; goserelin; IMC-EB10; IMGN-388; IPH-1101; MEDI-547; MGN-1706; OncoGel; PF-00562271; PF-03732010; PF-03758309; PF-04217903; PF-05057459; RG-7347; rilotumumab; SGN-40; SSR-97225; TAK-285; TAK-901; tenifatecan; TRX-518; XL-228; XL-888; zalatumumab; ZYC-101a
Categories
Funding
- Cancer Research UK Funding Source: Medline
Ask authors/readers for more resources
This year's analysis of discontinued drugs in oncology reveals that the trend of increasing numbers of candidate drug development terminations seen in recent years has continued into 2011. Thirty-seven drugs were dropped from the global oncology development pipeline in 2011, significantly more than the 28 discontinuations reported in 2010. Of note were the number of terminations reported for strategic reasons and the striking number of drugs (23) discontinued in or at the end of Phase I development. This article provides a summary of those drugs discontinued in 2011 and discusses the observations in the context of the rapid changes occurring in the way new anticancer drugs are developed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available